Project Grant R33HL167806
Award Date
5/1/25
Completion Date
4/30/29
Dollars Obligated
$776K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, DC 20010, USA
Similar Awards
This $179,280 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the impact of early life nutritional stress on neutrophil development and function in sickle cell disease (SCD). The research aims to determine if there is a critical window during early life when nutritional exposures can modulate lifelong neutrophil levels and activity, and how this relates to SCD...
This federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,103,783 to the University of Illinois from February 1, 2025 to January 31, 2032. The grant supports research to advance the understanding of the molecular and neurobiological mechanisms underlying chronic pain in sickle cell disease and develop effective pharmacologic treatments. The research applies molecular and cellular...
This $300,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by Gigamune, Inc. to develop an in vivo gene therapy approach for treating sickle cell disease. The project aims to assess the efficiency and specificity of a novel lentiviral vector platform for delivering CRISPR/Cas9 gene editing machinery to hematopoietic stem cells to knock out the BCL11A enhancer, with the goal of...
The University of Illinois was awarded a $607,535 Project Grant by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant, with an award date of September 17, 2024 and ultimate completion date of August 31, 2025, will fund research to evaluate the effects of hemin, a breakdown product of cell-free hemoglobin, on the pulmonary endothelium and its role in the development of pulmonary hypertension and acute chest...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,753.90 in funding to Bloodworks (also known as Puget Sound Blood Center and Program) to investigate the role of thiol isomerases in promoting redox-sensitive vaso-occlusion in sickle cell disease. The award period is from August 1, 2024 to July 31, 2027. The research aims to mechanistically examine how thiol isomerases,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $160,518 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Children's Research Institute (CRI) in Washington, DC. The grant, awarded on August 15, 2024, supports a Phase I clinical trial (NCT 05141058) to evaluate the safety and preliminary efficacy of using donor-derived SARS-CoV-2-specific T cells for prophylaxis against SARS-CoV-2 infection in patients after hematopoietic stem cell transplant. The...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the effects of sickle cell disease (SCD) red blood cells (RBCs) on neutrophil activation and phenotypes. The research aims to systematically define the characteristics of sickle RBCs that cause neutrophil activation, and the resulting functional, phenotypic, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 to Bloodworks (formerly Puget Sound Blood Center and Program) to conduct molecular and translational research on the mechanisms of disease in von Willebrand disease and sickle cell disease. The research aims to increase understanding of these blood disorders, identify new biomarkers, and explore potential new...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $265,347 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Functional Fluidics Inc., a minority-owned for-profit company in Detroit, Michigan. The goal of this Phase I grant is to develop and initially validate a microfluidic-based Dynamic Sickling Assay (DSA) as a point-of-care device to assess red blood cell sickling and monitor treatment progress in sickle cell disease patients. The proposed DSA...